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ImmunosuppressionUntil recently, the intrinsically high level of cross-talk between immune cells, the complexity of immune cell de-
velopment, and the pleiotropic nature of cytokine signaling have hampered progress in understanding themech-
anisms of immunosuppression by which tumor cells circumvent native and adaptive immune responses. One
technology that has helped to shed light on this complex signaling network is the cytokine antibody array,
which facilitates simultaneous screening of dozens to hundreds of secreted signal proteins in complex biological
samples. The combined applications of traditional methods of molecular and cell biology with the high-content,
high-throughput screening capabilities of cytokine antibody arrays and other multiplexed immunoassays have
revealed a complex mechanism that involves multiple cytokine signals contributed not just by tumor cells but
by stromal cells and a wide spectrum of immune cell types. This review will summarize the interactions
among cancerous and immune cell types, as well as the key cytokine signals that are required for tumors to sur-
vive immunoediting in a dormant state or to grow and spread by escaping it. Additionally, it will present exam-
ples of how probing secreted cell–cell signal networks in the tumor microenvironment (TME) with cytokine
screens have contributed to our current understanding of these processes and discuss the implications of this
understanding to antitumor therapies.
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Tumors are not homogenous population of cancerous cells; instead,
tumors are heterogeneous groups of cells from diverse origins, such as
stem cells, stromal cells, endothelial cells and a wide range of immune
cells [1]. These heterogeneous populations secrete multiple signals
that, individually and collectively, may promote or hinder any or all of
the hallmarks of cancer required for tumor growth, development, and
progression, as well as the enabling characteristics of genomic instabil-
ity and tumor-promoting inﬂammation [2]. The immune system is
constantly patrolling the body for foreign invaders and aberrant cells
to destroy, a process commonly referred to as immunosurveillance [3].
Thus, to remain viable and to continue to grow and thrive, tumors
must not just blunt the antitumor immune response in its microenvi-
ronment, the growing tumor must maintain other hallmarks of cancer,
such as avoiding apoptosis and maintaining self-sufﬁciency of growth
signals, inﬂammation, and angiogenesis [4].
Tipping the balance of immunosurveillance from tumor elimination
to tumor promotion appears to be a complex process that spansmultiple
signal pathways that can be inﬂuenced by cytokine expression from
tumor cells [5], immune cells [6], and other non-cancerous cell types,
such as epithelial cells or cancer-associated ﬁbroblasts (CAFs) [7], in
the surrounding tissue. Thus, net cytokine signal inputs from multiple
cell types in the tumor microenvironment (TME) can tip the overall bal-
ance in immunoediting from tumor-promoting to tumor-suppressing, or
vice versa. Aswedescribed in a previous review, cytokine biology is quite
complex [8]. How, then, does one go about decoding such a complex
network of multiple signals (some of which may be additive, antagonis-
tic, or synergistic) thatmay originate frommultiple potential sources and
pleiotropic effects on the heterogeneous cell types in the TME?
A proteomic technique that has shown great promise in detecting
key cytokines in cancers and in decoding tumor-related cytokine signal
networks is themultiplexed immunoassay [9–13]. The twomajor typesofmultiplexed immunoassays are antibody arrays (wherein capture an-
tibodies are printed on a planar solid support, such asmembranes, glass
slides, ormicrotiter plates) and bead-based assays, inwhich capture an-
tibodies are attached to ﬂuorescently-tagged beads. The capabilities,
challenges, advantages, and disadvantages associated with these vari-
ous multiplexed immunoassay technologies—compared with one an-
other and with more traditional approaches to proteomics and
genomics—have been well documented in the literature [8,13–17] and
are beyond the scope of this review.
However, the salient aspects of these methods that make them
useful are the sensitivity and speciﬁcity of immunoassays and the ability
to detect multiple proteins as once. Low-density bead-based assays and
antibody arrays may detect a dozen or so targets simultaneously, but
high-density (high-content) antibody arrays can potentially screen for
hundreds of proteins in as little as 20 μl of sample. Thus, targeted screens
for known inﬂammatory, angiogenic, apoptotic, or growth factors can
help identify key biomarkers related to cancer hallmarks from among
many potential candidates. High-density screens that allow for detec-
tion of cytokines with diverse functions may reveal crucial but unex-
pected expression of key factors by one or more cell types. Moreover,
the heterogeneous nature of tumors lends itself naturally to analysis
of the collective secretion proﬁles within tumor lysates or to dissect
secretion proﬁles of single cell types (cancerous or non-cancerous) or
co-cultures in vitro to discoverwhich cells are contributing these critical
signals and which cells are receiving them. After key factors are identi-
ﬁed by these cytokine screens, more traditional methods of cell biology,
molecular biology, and genetics can be used to complement these
results, conﬁrming and further dissecting and deﬁning the complex net-
work of secreted cell–cell signals and intracellular signaling pathways
that contribute to the biological process being studied. Thus, antibody
arrays are extremely powerful tools for the identiﬁcation of cancer-
speciﬁc biomarkers either secreted by cells in the local microenviron-
ment or by the cancer cells themselves.
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the cellular and secreted signaling networks that constitute the native
immune response to tumors and those that allow tumors to escape
immunoediting, as well as presenting some selected examples of how
multiplexed immunoassays, in conjunction with standard techniques
of molecular and cellular biology, have helped to shed light on these
complex processes. Unanswered and remaining questions will be
identiﬁed and implications of themechanisms of antitumor immune re-
sponse and tumor-induced immunosuppression on strategies for anti-
tumor therapies will be discussed.
2. Native antitumor immune response
2.1. Coley's observation: shared mechanisms of anti-bacterial and
antitumor immunity
The idea that the immune system could scan the body for microbial
pathogens and aberrant cancer cells and subsequently employ innate
and adaptive immune responses to eliminate them is not new; this the-
ory was conceived more than 100 years ago by Paul Erlich [18]. In the
1890s, physician William B. Coley had observed that tumors shrank in
some cancer patients with incident bacterial infections, and many ofFig. 1. A model of tumor-suppressing inﬂammation. Th1 lymphocytes and M1 macropha
immunosurveillance and cytotoxicity. Their interactions aremutually reinforcing: Secretion IFN
notype,while IL-12 producedbyM1macrophages recruits, activates andmaintains a Th1pheno
and CTLs and inhibits angiogenesis. IL-1α, IL-1β and IL-6 form an autocrine feedback loop by st
tion of NF-κB signaling. TNF-α, also released by the activation of NF-κB signaling, which activat
effector CD4+ T cells, and CD8+ cells, as well as the recruitment of NK cells.these patients appeared to be completely cured [19]. However, it was
not immediately apparent whether the mechanisms of immunity used
to ﬁght pathogens would be the same as for tumor clearance.
More recently, Agrawal, et al., used a xenograft model in mice to
test Coley's observation and found a molecular connection between
bacterial infection and shrinking tumors [20]. In their study, mice
bearing subcutaneous tumor xenografts (colorectal or renal cell carci-
noma) were injected with spores of Clostridium novyi-NT, an obligate
anaerobe. This initiated C. novyi-NT infection exclusively within tumors,
and hemorrhagic necrosis of tumors began within 24 h. After the bacte-
rial infection resolved, tumors returned in 66% of mice, but the other
34% remained tumor free for at least 60 days. Similar results were
obtained using tumor-bearing rabbits. Moreover, this effect was long-
lasting, as 80% of mice and 100% of rabbits cured of tumors by
C. novyi-NT inoculation resisted further tumorigenic challenges for
months after the initial treatment. Cytokine antibody array analysis,
screening for expression of 32 different proteins at once, revealed that
C. novyi-NT infection in tumor-bearing mice increased serum levels of
several inﬂammatory markers, including IL-6, MIP-2 (GRO-β)/CXCL2,
G-CSF/CSF3, TIMP-1, and KC (GRO-α)/CXCL1. These cytokines also
attracted a massive inﬂux of pro-inﬂammatory cells, largely neutro-
phils, followed within a few days by monocyte and lymphocyteges are the primary sources of pro-inﬂammatory cytokines that also promote cancer
-γ by Th1 cells results in the recruitment of M1macrophages andmaintenance ofM1 phe-
type. Secretion ofMIG/CXCL9 and IP-10/CXCL10 also promotes the recruitment of Th1 cells
imulation of myeloid differentiation primary response gene 88 (MyD88)-mediated activa-
es APC functions of DCs and the recruitment and cytotoxic activation of M1 macrophages,
185B. Burkholder et al. / Biochimica et Biophysica Acta 1845 (2014) 182–201inﬁltration. These, in turn, initiated a cell-mediated tumor immune re-
sponse, primarily by cytotoxic T cells, characterized by the expression
of cluster of differentiation protein 8 (CD8+) on their surface, that
inhibited tumor growth even when transplanted to uninfected tumor-
bearing mice.
2.2. A model of native antitumor inﬂammation
Awide range of “antitumor” immune cells are known to support the
clearance of tumor cells, including T helper type 1 (Th1) cells, cytotoxic
CD8+ T lymphocytes (CTLs), natural killer (NK) cells, natural killer T
(NK-T) cells, type 1 macrophages (M1), type 1 neutrophils (N1),
eosinophils, and mature dendritic cells (DCs) [21–24]. However, some
cancers appear to beneﬁt from increased numbers of Th1 cells, and par-
adoxical roles for CTLs and NK-T cells in cancer have also been reported
[21,22,25,26]. A model of the immunostimulatory effects of Th1 andM1
cells resulting in antitumor inﬂammation was recently published by
Haabeth et al., in which they depicted results of their studies of the
cytokine proﬁles of inﬁltrating immune cells in a collagen gel matrix
[21,27]. The cytokines trapped in the gel were measured by cytokine
multiplexed bead assays, and the immune cell types were characterized
by cell surface antigens usingﬂow cytometry or immunohistochemistry
(IHC). Using this approach, they discovered that tumor-suppressive in-
ﬂammation in the early immune response is regulated by a relatively
small number of cytokines (summarized in Fig. 1).
Th1 and M1 cells were the predominant T helper and macrophage
phenotypes in the TME of the collagen matrix. Production of IL-1α
and IL-1β from M1 cells enhanced B cell proliferation and antibody
production, increased antigen-presentation cell (APC) capabilities of
DCs, synergized with IL-2 to stimulate proliferation of cytotoxic cells
and the proliferation and differentiation of CD4+ effector T cells, and in-
creased the cytotoxicity of M1 cells by an autocrine (positive feedback)
loop via stimulation of MyD88-mediated activation of NF-κB signaling.
IL-6 also stimulated B cell proliferation, differentiation, and antibody
production, increased the antitumor activity of CD4+ and CD8+ T
cells, and promoted the differentiation and activation of M1 cells by
an autocrine loop. MIG/CXCL9 and IP-10/CXCL10 increased the
recruitment of Th1 and CTLs to the gel matrix and inhibited angiogene-
sis. TNF-α, also up-regulated by the activation of NF-κB signaling, was
important for the activation of APC functions of DCs and the recruitment
and cytotoxic activation of M1macrophages, effector CD4+ T cells, and
CD8+ cells, as well as the recruitment of NK cells. When stimulated by
IFN-γ and TNF-α, Th1 cells are efﬁcient at arresting cancer progression
[25,28]. Additionally, Th1 andM1 cellsmutually reinforced one another,
with Th1-produced IFN-γ driving the differentiation and activation of
theM1 phenotypewhile M1-produced IL-12 reinforced the Th1 pheno-
type. Thismodel clearly illustrates the importance of Th1 andM1 cells in
antitumor immunity, which has been well established in the literature
[21,25]. Importantly, levels of M1 macrophages and Th1 lymphocytes
in the TME have been positively correlated with prognosis and survival
times in many cancers [29–32].
While it is clear that induction of a vigorous inﬂammatory response
is one of the primary mechanisms of native immune responses to
tumors, the inability to resolve chronic inﬂammation is widely consid-
ered one of the primary causes of carcinogenesis. About 20% of cancers
are linked to inﬂammation associated with chronic infections [33]. In
stomach cancer, for example, the most established risk factor is chronic
gastric infection byHelicobacter pylori [34]. Chronic inﬂammation in the
TME is a major contributor to angiogenesis, invasion and metastasis
[23,35]. In addition to enhancing the proliferation of mutated cells, in-
ﬂammatory microenvironments can also increase mutation rates. Acti-
vated inﬂammatory cells serve as sources of reactive oxygen species
(ROS) and reactive nitrogen oxide species (RNOS) that are capable of in-
ducing DNA damage and genomic instability [23,26]. The clinical signif-
icance of this was recently conﬁrmed in a study that reported lower
rates of both somatic genomic anomalies and progression to esophagealadenocarcinoma in patients with Barrett's esophagus who routinely
took non-steroidal inﬂammatory drugs (NSAIDs) [23,36].
2.3. Immunosurveillance & immunoediting: elimination, equilibrium and
escape
A second mechanism of antitumor immunity is known as
immunosurveillance: the identiﬁcation and elimination of tumor cells
by the immune system. This was ﬁrst proposed in the 1950s by Sir
Macfarlane Burnet and Lewis Thomas (reviewed in [3]). Results of
early testing of the immunosurveillance concept in mouse models, pri-
marily in immunocompromised mice, such as nude mice, were either
inconclusive or contradictory to its central predictions, and by the late
1970s the concept was all but abandoned. By the late 1990s, however,
following the discovery of cytotoxic cells, such as NK cells [37], the elu-
cidation of the critical role of antigen presentation by DCs [38] and the
development of severe combined immune-deﬁcient (SCID) mice [39],
studies of mechanisms of antitumor immunity that were dependent
on IFN-γ [40], perforin [41,42], and T-cell receptor (TCR) interactions
with antigens bound to the surfaces of APCs by MHC proteins [43]
presented strong evidence for cancer immunosurveillance due to both
humoral and adaptive immune responses. The prominent role of
immunosurveillance in the natural defenses opposing tumorigenesis
was illustrated by signiﬁcant increases seen in spontaneous tumor inci-
dence in immunodeﬁcientmice strains, such as SCIDmice,which collec-
tively represent disruptions in more than two dozen immune-related
genes [44,45].
Activation of both CD8+ cytotoxic T lymphocytes (CTLs), including
αβ T cells, γδ T cells, NK cells, NK-T cells, and effector (CD4+) T cells
by antigen presentation is critical for tumor elimination via
immunosurveillance [25]. Moreover, inﬁltration of CTLs and effector T
cells in the tumor microenvironment is a critical factor in prognosis
for many cancers [29,30,32]. Two separate signals are required to acti-
vate the adaptive immune response in naive T cells (see Fig. 2). The
ﬁrst is generated by TCRon naive T cells binding to an antigen presented
by an MHC expressed on the surface of another cell. Antigen presenta-
tion by mature DCs (Fig. 2A) is considered to be critical for potent anti-
tumor immune responses by CD4+ T cells. CD4 on CD4+ T cells bind to
class II MHC (MHC-II), which can be expressed on any cell type, but pri-
marily by cells specialized for APC (macrophages, B cells, and DCs). TCRs
and CD8 on CTLs bind to class I MHC molecules (MHC-I), which are
expressed on the surface of all mammalian cells except red blood cells
(Fig. 2B). The second signal is provided by interaction of CD28 protein
on the T cell with B7-1 (CD80) or B7-2 (CD86) on the surface of the
APC. Failure of the T cell to receive the second signal generally results
in T cell anergy (inactivation). This can also be accomplished by interac-
tion of the CD28 ligands (CD80 and/or CD86) with a co-inhibitory
molecule, CTLA-4; this is part of the natural fail–safe mechanism to
limit overactive immune responses that could lead to an auto-immune
disease. As we shall see in Sections 7.1 and 7.2, CTLA-4 is a target for
immunotherapy that is generating much interest because it is almost
exclusively expressed on T cells, including immunosuppressive regula-
tory T cells (TREGs) [46,47].
Effective antitumor immune responses lead to the targeting and
elimination of tumor cells and, ultimately, shrinkage of the tumor. How-
ever, immunosurveillance can create selective pressure for tumor cells
that may suppress certain cell surface markers or otherwise gain the
capability to persist in equilibriumstate (dormancy) or to escape antitu-
mor immune responses entirely, leading to tumor progression. Collec-
tively, the processes of immunosurveillance and its three possible
outcomes—elimination, equilibrium and escape—are referred to as
immunoediting (see Fig. 3) [3,48]. Both innate and adaptive immunity
appear to be involved in elimination, and inhibition of both innate and
adaptive immunity is important for the ultimate success of tumors
achieving escape, but it is the adaptive immune system that is primarily
responsible for maintaining occult tumors in equilibrium [45].
Fig. 2. Antigen presentation and T cell anergy. T lymphocytes become activated via a two-signal process in which 1) T-cell receptor must bind to an antigen presented on a major histo-
compatibility complex (MHC) protein expressed on the cell surface of another cell, and 2) CD28 must concurrently bind with its ligands, B7-1 or B7-2. Without this second signal, T cell
anergy (inactivation) will result, and the adaptive immune response is inhibited. As part of a fail–safe mechanism to prevent over-active autoimmune responses, T cell anergy may also
result if the co-inhibitory receptor cytotoxic T lymphocyte-associate protein-4 (CTLA-4) competes to bind CD28 ligands or if programmed death-1 (PD-1) receptor binds its ligand, PD-L1.
A) CD4 antigens on naive CD4+ lymphocytes (activated T cells and T helper cells) bind speciﬁcally to type II MHC (MHC-II, which can be expressed on any cell, but interactions with
dendritic cells (DCs) are professional antigen presenting cells (APCs) are critical for antitumor immunity; B) CD8 antigens on naive CD8+ cytotoxic lymphocytes (CTLs) bind speciﬁcally
to type I MHC (MHC-I), which can be expressed on any cell except red blood cells. Tumor cells may present their own antigens on their cell surface via MHC-I, albeit poorly. Other antigen
presenting cells, such as M1 macrophages or B cells may also activate CTLs via MHC-I-mediated APC activity.
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As evident by Coley's observation and subsequent investigations, in-
ﬂammation and immunosurveillance can cooperate to suppress tumors.
However, just as normal cells use cytokines to regulate native immune
responses, tumor cells have developed mechanisms to escape them.
These effects are not systemic, but localized; tumor cells create immu-
nosuppressive zones within the TME [22,49]. How then is the balance
of immunoediting altered in the TME to suppress antitumor immune re-
sponse and to promote tumor progression? The key to tumors gaining
the ability to escape immunosurveillance appears to be four-fold: 1)
by altering expression of cell surface markers used by the adaptive im-
mune system to identify and to target them; 2) by acquiring resistance
to apoptotic or necrotic mechanisms normally induced by cytotoxic
cells as a result of being targeted; 3) by directly suppressing the adap-
tive and innate immune response of activated T cells and cytotoxic im-
mune cells; and 4) by altering the balance of both adaptive and innate
immune cell populations in the TME tomaintain tumor-induced immu-
nosuppression. A ﬁfth possible mechanism of tumor “escape” is metas-
tasis. Just as immunoediting can put selective pressure on cancer cells to
alter cell surface markers, there is a growing body of evidence that,
particularly in advanced cancers, highly effective immunosurveillance
in the TME may place sufﬁcient selective pressure on tumor cells popu-
lations to result in the emergence of highly mobile tumor cells within
the necrotic/apoptotic tumor [50]. The result may be that the remaining
cells withmetastatic capabilitiesmay attempt to “escape” by evacuating
the now hostile TME in search of more tumor-friendly environments.3.1. Changes in tumor-associated antigens
One possible mechanism is for tumor cells to cease or change ex-
pression of tumor-associated antigens (TAAs) thatmake them easy tar-
gets for immunosurveillance. It is even plausible that this mechanism
will induce a selective pressure, killing tumor cells that express TAAs
and leaving only tumor cells expressing fewer immunogenic surface an-
tigens to proliferate. This was recently conﬁrmed using a genetically
engineered mouse model that was used to monitor the onset and
growth of immunogenic and non-immunogenic tumors induced in
situ [51]. In immune-competent mice, primary tumors in the mice
became less immunogenic over time through the selective outgrowth
of cells lacking certain TAAs that enabled them to escape
immunosurveillance. Moreover, results from mice deﬁcient in antigen
presentation of TAAs via MHC-I proved that APC activity was both
necessary and sufﬁcient for this immunoediting process to occur.
Since tumors themselves can present TAAs via MHC-I expression, loss
of molecules important to the innate antigen presentation mechanisms
in tumor cells, includingmutations or silencing of genes related to IFN-γ
signaling (receptors or downstream effectors) can lead to a lack of im-
mune response to IFN-γ [52].
3.2. Changes in susceptibility to cytotoxic response
A related mechanism is for the tumor cell to render themselves less
susceptible to the apoptotic and necrotic effects of immune cell
targeting. This might include up-regulation of anti-apoptotic proteins
Fig. 3.Amodel of immunoediting in tumor progression. Normal cells may become nascent tumors by evading tumor suppression after carcinogenic mutation and/or apoptosis that would
normally result from gross chromosomal changes. Pro-inﬂammatory and pro-angiogenic factors can help to establish blood supply for the growing nascent tumor. Activation of the adap-
tive or native immune response can eliminate the nascent tumor, the tumormay remain in equilibrium as an occult tumor, or the tumormay escape immunosurveillance to create a viable
tumor-supportive microenvironment. Innate and adaptive immune responses may still work to eliminate the tumor via immunosurveillance. Tumors may also metastasize to move to
another location; this may be an additional mechanism of avoiding immunosurveillance by evacuation of the “hostile” TME. Green color denotes processes potentially leading to tumor
eradication, while red color means promoting tumor escape and progression.
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face, such as TRAIL receptors or Fas. These, of course, are characteristics
that are related to avoiding apoptosis, another cancer hallmark,
(reviewed in [4,53]). Further details of this process are beyond the
scope of this review.3.3. Direct immunosuppression of activated T cells and cytotoxic cells by
tumors
Although B cell-mediated adaptive immunity is an integral part of
the antitumor response, mechanisms of T cell-mediated innate and
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pear to be the primary targets of tumor-induced immunosuppression.
Some of these effects are directly mediated by the tumor cells them-
selves (reviewed in [45]). For example, many tumor cells have demon-
strated increased expression of IDO, which depletes tryptophan (an
important amino acid for CLT proliferation and survival of CD4+ T
cells) by converting it to kynurenines, which inhibits T cell activation.
Secretion of galectins, such as galectin-1 (LGALS1) [54] can impede T
cell activity and survival, as well as stimulate angiogenesis.
Shedding of MHC protein homologs A or B (MICA or MICB), which
are ligands for NKG2D, a receptor found on NK and other immune
cells, can render tumor cells unrecognizable by cells expressing
NKG2D and can even decrease NKG2D expression on these cells, as
these receptors are subject to endocytosis upon binding their ligand
[55]. Tumors can directly inhibit immune cell activities by expression
of certain molecules on the cell surface of tumors, such as HLA-G,
HLA-E and PD-L1. Another component of the immune system's fail–
safe mechanism to prevent over-activation is PD-1, which is expressed
on T lymphocytes. If PD-1 on the surface of an activated T cell interacts
with its ligand, PD-L1 (also known as B7-H1) concurrently with TCR
binding to an antigen presented by MHC, T cell “exhaustion” can result
in reduced immune response due to lower cytotoxic activity and/or the
induction of T cell apoptosis (Fig. 4). For this reason, PD-1 has also
become a target for cancer immunotherapy, which will be further
discussed in Section 7.2.
Finally, cytokines that have direct immunosuppressive effects can be
secreted by tumor cells themselves, including TGF-β and VEGF; the im-
portant roles of these molecules will be discussed in greater depth in
Sections 5 and 7. However, it appears that tumor-directed changes inFig. 4. T cell “exhaustion” via CTLA-4 and/or PD-1. Effector T cells (activated CD4+ T cells
or T helper cells) may be “exhausted” (inactivated) by programmed death-1 receptors
(PD-1) on their surface binding to PD-L1 ligands on target tumor cells. Also, regulatory T
cells (TREGs) can exhaust effector T cells by CTLA-4 on their cell surface binding to B7-1
or B7-2 on tumor cells, which releases a soluble factor that causes effector T cell “exhaus-
tion”; a likely suspect for this effect is TGF-β1.immune cell populations in the TME are the most complex and impor-
tant mechanisms of tumor-induced immunosuppression.
3.4. Tumors-directed changes in immune cell populations
Tumor cells appear to recruit, “educate” andmaintain populations of
cancer-associated ﬁbroblasts (CAFs), endothelial cells, and tumor-
promoting immune cell types that, collectively, suppress antitumor
immune cell types while maintaining sufﬁcient inﬂammatory and an-
giogenic potential in the TME to promote tumor growth and progres-
sion. Immune cells that tend to promote tumor progression via
immunosuppression include type 2 macrophages (M2), Th2 CD4+
cells, regulatory T (TREG) cells, activated B cells, and type 2 neutrophils
(N2) [21,22,24,49]. Importantly, there appear to be synergistic and mu-
tually reinforcing cytokine signal networks between tumor-suppressing
immune cells, in which Th2 cells, tumor-associated M2 macrophages
and N2 neutrophils (TAMs and TANs, respectively), B cells, granulocytic
myeloid-derived suppressor cells (MDSCs), and TREGs all appear to play
crucial roles, as summarized in Fig. 5 [21,22,25,26,56].
It should be noted that plasticity is an inherent quality of immune
cells, as all of them are derived from a relatively small number of pro-
genitor cells that all mature from a single pluripotent hematopoietic
stem cell population. Also, as recruited cell populations in tumors can
vary between cancer types, the following descriptions of immune cell
phenotypes in the proposed model below may not hold true for every
type of cancer, and novel, unexpected phenotypes of immune cell pop-
ulations are likely to be encountered as their interactions in the TME are
further elucidated. An example of the plasticity of immune cell pheno-
types is the characterization of some unusual peritoneal macrophages
(T-PEMs) in tumor-bearing mice by a group at the University of
Miami; T-PEMs exhibited increased expression of granulocytic myeloid
(Gr-1)markers and reduced CD11b expression, which is more a charac-
teristic of MDSCs than macrophages, and antibody array analysis
revealed that their secretion proﬁles were neither M1 nor M2 and
were less differentiated than either phenotype [57]. T-PEMs were
deﬁcient in producing M1 inﬂammatory markers (IL-12 p40 and p70,
IL-1β, IL-6, TNF-α, MCP-1/CCL2 and M-CSF/CSF1), but they did not ex-
hibit an increase in expression of M2-related cytokines. The authors
noted that TGF-β and prostaglandin E2 (PGE2) were likely suspects in
the etiology of these unusual monocytes, as treatment of their progeni-
tor cells with TGF-β and PGE2 synergistically lowered expression
of transcription factors NF-κB and CAAT/enhancer binding protein (C/
EBP); similarly low levels of NF-κB and C/EBP expression were seen in
cultured T-PEMs.
That being said, the immune cell phenotypes described below are
employed as a useful oversimpliﬁcation to illustrate complex interac-
tions among various immune cells with each other and non-immune
cell types, resulting in tumor-directed alterations of immune cell
populations that suppress the native immune response in the TME.
4. Essential immune cell populations in
tumor-induced immunosuppression
4.1. T helper cells: tipping the Th1/Th2 balance
An overview of T helper cell differentiation is presented in Fig. 6. Th1
and Th2 cell populations are both derived from naive, precursor CD4+ T
helper (Th0) cells. If Th0 cells are exposed to IL-12, they tend to differ-
entiate into Th1 cells; conversely, Th2 cells arise from the differentiation
of Th0 cells exposed to IL-4 and IL-13. Cytokines released by Th1 cells
are those typically associated with cytotoxic function: TNF-α, IFN-γ,
IL-2 and IL-12. Collectively, these cytokines enhance the cytotoxic capa-
bilities of M1 macrophages, CTLs, NK cells, and NK-T cells. Th1 cytokine
responses are typical of those induced by microbial infections. Th2 cells
are more commonly associated with asthma, allergic responses, and
Fig. 5. Tumor-supporting immune cell interactions. Th2 lymphocytes, M2 macrophages and MDSCs mutually reinforce the proliferation and phenotypes of one another, as well as
maintaining tumor-promoting inﬂammation and angiogenesis. These cells, along with T regulatory lymphocytes (TREGs) suppress the activity and proliferation of tumor-suppressing
cells, including Th1, M1 and cytotoxic T cells and NK cells. It should be noted that M1 &M2macrophages can interconvert, but these phenotypes are stable as the M1 and M2 expression
proﬁles reinforce their ownmacrophage phenotypes, while suppressing the other. Similarly, Th1 & Th2 lymphocytes, as well as TREG & Th17 lymphocytes tend to self-reinforce their own
activation proﬁles and inhibit the other.
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are characterized by high levels of IL-4, IL-5, IL-6, IL-10, and IL-13.
The ratio of Th1 to Th2 cells is commonly referred to as the Th1/Th2
balance. Importantly, Th1 and Th2 cells produce cytokine proﬁles that
are antagonistic to one another; that is, Th1 or Th2 cells tend to release
cytokines that self-reinforce the differentiation and activation of
populations of T helper cells of their own phenotype and inhibit the dif-
ferentiation and activation of the other. As depicted in Figs. 1 and 6, both
IL-12 and IFN-γ contribute to a positive feedback loop to reinforce Th1
differentiation. Further, transcriptional factors associated with IL-12
signaling increase transcription of IFN-γ and other Th1 cytokines but in-
hibit transcription of IL-4, while transcriptional factors activated by IL-4
induce expression of Th2 cytokines and inhibit expression of IL-12 Rβ
[58]. Moreover, Th1 and Th2 appear to be terminally differentiated
cells with limited plasticity. Thus, once a population of Th1 or Th2
cells is established, they tend to be very stable. In cancer, these signals
work in concert not only to suppress Th1 cell maturation and to pro-
mote Th2 maturation but also , further, to inhibit T-cell-mediatedcytoxicity, to promote the humoral immune responses of B cells, and
to educate tumor-associated macrophages (TAMs) [25,59].
4.2. Macrophages: tipping the M1/M2 balance
As we saw in Section 2.2, early in tumorigenesis, macrophages
attracted to the TME may exhibit classically activated inﬂammatory
phenotypes (M1) to support immune response to the nascent tumor,
resulting in the secretion of large amounts of IL-12, IL-1α, IL-1β, IL-6,
TNF-α, and IFN-γ by Th1 lymphocytes (see Fig. 1), as well as the
induction of nitric oxide (NO) and ARG1 expression by M1 macro-
phages, which increases CTL cytotoxicity. However, as the tumor pro-
gresses, macrophages in the TME often tend toward an alternatively
activated, immunosuppressive (M2) phenotype [60], commonly called
TAMs, which have been demonstrated to be induced by exposure to
IL-4, IL-13, M-CSF/CSF-1, IL-10 and TGF-β1, among other factors. TAMs
support tumor growth, survival, and metastasis and are attracted to
the TME by M-CSF/CSF-1, SDF-1/CCL12, and MCP-1/CCL2, which may
Fig. 6. T-helper cell differentiation. All T helper lymphocytes are differentiated cell types derived from the same common immature T helper progenitor (Th0). Depending upon what
cytokines the Th0 cells are exposed to, they may differentiate into one of several different T helper phenotypes: type 1 T helper cells (Th1), type 2 T helper cells (Th2), T regulatory
(TREG) or type 17 T helper cells (Th17). Th1 and Th2 cells are generally considered terminal, permanent phenotypes. Some in vitro evidence suggests that TREG and Th17 cellsmay be some-
whatmore plastic; the cytokines implicated in these proposed inter-conversions of T helper types are indicated by a questionmark (?). However, neither reversion of any of these T helper
types back to a Th0 progenitor phenotype nor conversion of Th17 cells to a TREG phenotype have been reported.
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[25,59,60]. Roca et al., examined the regulation of immature monocytes
(CD11b + cells) by MCP-1/CCL2 [61]. Using cytokine antibody arrays,
they demonstrated that CD11b+ monocytes produce MCP-1/CCL2 and
low levels of IL-6. They also discovered that expression of IL-6 and
MCP-1/CCL2, two of themost common cytokines in the TME,wasmutu-
ally reinforcing,wherein stimulation of CD11b+ cells byMCP-1/CCL2 in-
creased IL-6 protein secretion 5-fold and, when induced by IL-6,
expression of MCP-1/CCL2 rose 2-fold. This synergistic up-regulation
of IL-6 and MCP-1/CCl2 pushed CD11b+ monocyte differentiation to-
ward the M2 macrophage phenotype, and protected both cell types
from cell death by inhibiting apoptosis.
M2macrophages also typically secrete large amounts of growth fac-
tors, such as EGF, inﬂammatory factors (such as COX2) and angiogenic
factors, including VEGF and angiogenic chemokines, into the TME.
TAMs also play a prominent role in inﬂammation and angiogenesis, as
well as in tumor progression and metastasis (reviewed in [59,62]).
Higher densities of TAMs in tumors and overexpression of key instiga-
tors of M2 differentiation are considered markers of poor prognosis in
a number of cancers [63].4.3. Dendritic cells: eliminating antigen presentation
Dendritic cells (DCs) play a crucial role in the interface of adaptive
immunity by engulﬁng foreign antigens and by migrating to lymphoid
organs to present them to adaptive immune cells. Levels of antigen-
presenting DCs in the TME and in peripheral blood are positively associ-
ated with good prognosis and inversely correlated with poor prognosis
inmany cancers [64–67]. An important inhibitor of DC-mediated tumor
suppression is PGE2, the product of COX2. The addition of COX inhibitors
or neutralizing antibodies recognizing PGE2 blocked the immunosup-
pressive effects of supernates from Lewis lung carcinoma cell cultures
on DCs, speciﬁcally by increasing DC production of IL-10 and lowering
DC expression of IL-12 [68,69]. Previous studies have demonstrated
that PGE2 supports Th2 proliferation and that Th2-associated cytokine
expression both limits the production of IFN-γ directly and opposes
IL-12 signaling on multiple levels [70]. Several cytokines are also
known to impair tumor suppression by DCs as well, including GM-
CSF/CSF2, IL-10, and VEGF [71]; all of these appear to work, at least in
part, by augmenting COX2- and PGE2-induced proliferation of MDSCs
[72]. Moreover, a positive feedback loop involving COX2 and PGE2appears to redirect development of immature DCs away from matura-
tion as Th1-inducing DCs (DC1 subtype) and toward their differentia-
tion as tumor-promoting MDSCs [72]. Thus, the inhibition of DC
maturationmay prove to be a critical aspect of tumor escape, as it blunts
antigen presentation and cytotoxic responses by DCs, as well as provid-
ing more immature DC progenitors to reinforce M2 macrophage and
Th2 T-cell phenotypes in the TME. COX2 and PGE2 are also major con-
tributors to tumor-promoting inﬂammation and angiogenesis, two pro-
cesses in cancer progression that appear to be interdependent and,
therefore, inextricably linked (see Sections 5.4 and 7.4) [47,73,62]. Fi-
nally, tumor-educated, immature (CD11c+/CD11b+) DCs are also sig-
niﬁcant source of TGF-β and appear to be essential to the proliferation
of TREGs via the induced secretion of TGF-β [74].4.4. Immature myeloid cells: MDSCs
MDSCs are elevated in virtually all patients and experimental mice
with malignancies and have been linked to both inﬂammation and
tumor-directed suppression of immune response [75]. MDSCs are a het-
erogeneous group of cells, but in mice, all of them appear to share ex-
pression on their surfaces of the granulocytic myeloid (Gr-1) markers
Ly6C and/or Ly6G, which are typically characteristic of macrophages
and macrophage marker CD11b (Gr-1+CD11b+). MDSCs are known to
inhibit the proliferation of CD4+ and CD8+ T cells, to block the activa-
tion of NK cells, and to polarize T helper maturation to a Th2 (tumor-
promoting) phenotype. Recent reports show that COX2, PGE2, and IL-
6 may have a role in the differentiation and proliferation of MDSCs,
but beyond that, little is known of the cytokine or other secreted factors
that may lead to the differentiation of MDSCs from less differentiated
monocyte progenitors [72,76]. However, an inverse relationship be-
tweenMDSCs and DCs is clear. MDSCs and DCs do share a common pro-
genitor: MDSCs can be converted to DCs with all-trans retinoic acid.
Proliferation of MDSCs also seem to be inversely correlated with levels
of mature DCs in cancer, as was noted byMattei, et al., in amouse strain
deﬁcient in the transcription factor IRF-8. In IRF-8-deﬁcient (Irf8−/−)
mice, melanoma cells grew more rapidly, leading to higher number of
lung metastases [77]. Also, Irf8−/−mice exhibited poor homing of DCs
and T cells to tumors, while exhibiting larger numbers of MDSCs in
the spleen and tumors. They also conﬁrmed by antibody array and
quantitative PCR that IL-3 and IL-6 expressions in splenocytes from
Irf8−/−mice were signiﬁcantly increased, but that expression of IL-10
Fig. 7. Thwarting of IFN-γ-mediated immune response by TREGs and MDSCs. Interferon-
gamma (IFN-γ) can initiate a powerful immune response as outlined in Fig. 1. However,
interactions between CD40 receptors on myeloid-derived suppressor cells (MDSCs) and
CD40 ligand (CD40L) on regulatory T cells (TREGs) can short-circuit this response by releas-
ing a number of immunosuppressive cytokines. This results in decreased production of
IFN-γ and IL-2 in the TME due to the suppression of Th1 activation and the promotion
of Th2 polarization, as well as a concomitant decrease in the activation and cytotoxic activ-
ity of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. Additionally, CD40 re-
ceptor expression on MDSCs is increased.
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with IL-6 and/or IL-27 demonstrated that treatment of with IL-27
could increase IRF-8 production and that co-treatment with IL-6 and
IL-27 was synergistic.
MDSCs also have a key role inM1/M2 balance [78]. M1macrophages
are activated by IFN-γ and express low levels of IL-10 and high levels of
IL-12, which reinforces Th1 populations and drives maturation of DCs.
IL-12 has been shown to reverse M2 phenotypes in TAMs and to induce
tumor regression associated with the appearance of activated NK and
tumor-speciﬁc CTLs [79]. MHC-II also supports a role for macrophages
in antigen presentation, which may not be as prominent or important
as that for DCs. However, in the presence of IL-10, direct contact be-
tween MDSCs and M1 macrophages causes down-regulation of IL-12
transcription and MHC class II (MHC-II) expression in macrophages,
which effectively shuts downAPC activity in DCs andmacrophages, pro-
foundly limiting immunosurveillance by the adaptive immune system
[78]. MDSCs also inhibit the cytotoxic functions of NK, B and T cells by
the secretion of arginase-1 (ARG1) and NOS2 in the TME [80]. ARG1 de-
pletes L-arginine, a critical factor in T-cell activation and a precursor of
nitric oxide (NO) production by NOS2. When NOS2 activity is high
and L-arginine levels are low, instead of producing NO, NOS2 starts pro-
ducing ROS and RNOS, which results in inﬂammation, T-cell anergy and
carcinogenic DNA damage to the surrounding tissue. Some groups have
reported thatMDSCs promote tumor development by enhancing angio-
genesis and by inhibiting T lymphocyte-mediated antitumor immunity
[22]. A xenograftmodel of lungmetastases induced by4T1 breast cancer
cells in BALB/c mice conﬁrmed the important role that MDSCs play in
tumor immune suppression [81]. ELISPOT analysis demonstrated that
MDSCs signiﬁcantly lowered IFN-γ expression in tumor-bearing tissues.
IFN-γ is a potent antitumor cytokine, suggesting that MDSCs play a
major role in tumor-induced immunosuppression. MDSCs also help
the proliferation of immunosuppressive T cells commonly called
TREGs; the clonal expansion of TREGs is dependent on TGF-β and IL-10 se-
creted by Gr-1+CD11b+ MDSCs [74]. High levels of MDSCs in the TME
and peripheral blood have been correlated with poor prognosis and
shorter median survival times for several distinct cancer types [76].
4.5. Regulatory T helper cells: TREGs
Regulatory T (TREG) cells play an important role in preventing im-
mune responses to self-antigens, but increased numbers of TREG cells
in peripheral blood and TMEs are commonly seen in patients with inva-
sive and metastatic cancers [82]. TREGs are generally identiﬁed as T cells
that express CD4, CD25 and FOXP3 proteins on their surfaces
(CD4+CD25+FoxP3+ T cells) that are normally found in lymphoid
tissues; however, they are preferentially recruited to tumors and associ-
ated ascites via MDC/CCL22—presumably by binding to CCR4, which is
also expressed on TREGs—and are a signiﬁcant predictor of poor patient
prognosis [83]. CD40 expression on MDSCs interacting with CD40L on
TREGs in the presence of TGF-β and IL-10 appears to be necessary for
the expansion of TREGs, as MDSCs from Cd40-deﬁcient mice and mice
injected with anti-CD40 were unable to expand TREG populations and
exhibited higher levels of tumor-speciﬁc T-cell immune response [84].
Further, IFN-γ appears to increase the expression of CD40 [84], IL-10,
and TGF-β by MDSCs [85] (see Fig. 7). However, beyond this, little is
known of their role in the cytokine network because, the mechanisms
by which TREG cells mediate immunosuppression in cancer have been
largely ignored [86]. Instead, interest in TREGs has beenmainly as an im-
portant target for immunotherapy of cancer (see Section 7.1 and 7.2).
5. Key cytokine signaling networks in immunoediting and escape
At themolecular level, TGF-β, Th2 cytokines (including IL-4, IL-5, IL-6,
IL-10, IL-12, and IL-13), chemokines (particularly angiogenic
chemokines), VEGF, inﬂammatory factors and GM-CSF, all appear to
play major roles in the avoidance of cancer immunosurveillance.Owing to the large number of secreted signals involved, multiplexed im-
munoassays that screen for changes in protein expression of a wide
range of targets have been very helpful in decoding the cytokine
crosstalk that promotes tumor-induced immunosuppression. A summa-
ry of the key immune cell types and cytokines involved in tumor-
induced immunosuppression is presented in Figs. 5 and 8, the latter
emphasizing the importance of TGF-β signaling andmediators of inﬂam-
mation and angiogenesis to maintaining immunosuppressive networks.
5.1. Transforming growth factor beta (TGF-β)
TGF-β signaling has been referred to as a double-edged sword in car-
cinogenesis [87]. TGF-β signaling is known to induce arrest of the cell
cycle in G1 and appears to play a major role in tumor suppression in
early tumorigenesis; however, in later stages, TGF-β signaling in the
TME is thought to enhance tumor progression. TGF-β directly inhibits
the cytolytic activity of NK cells, macrophages, and CTLs and can inhibit
the clonal expansion of NK cells and CTLs [88]. Nam et al., utilized cyto-
kine antibody arrays to help reveal the mechanism by which CD8+ T
cells, a precursor of cytotoxic T cells, could be subverted in the TME to
promote survival of breast and colorectal tumor cells [89]. They also
found that CD8+ cells, when exposed to tumor-secreted IL-6 and TGF-
β in vitro or in vivo, began to express IL-17, which directly promoted
tumor growth and survival. They proposed a model in which TGF-β
blocked the differentiation of CD8+ T cells to cytotoxic T cells, which
would be likely to attack cancer cells, and IL-6 and TGF-β promoted
the expression of IL-17 in CD8+ T cells. TGF-β signaling also appears
to play signiﬁcant roles in tumor immunoediting by affecting the com-
positions of B cell populations. Although B cells are known to express
Fig. 8. Cooperativity of cancer-promoting immune cells in the TME. In the TME, a positive feedback loop of cytokine signals that proceeds as follows: First, TGF-β, COX2, PGE2, Th2-
associated inﬂammatory factors and proangiogenic proteins are secreted by cancer cells, CAFs and other cell types in the nascent tumor recruit Th2 lymphocytes, M2 macrophages
(TAMs) andN2 neutrophils (TANs). Then, Th2 lymphocytes, TAMs andTANs secrete additional inﬂammatory andproangiogenic proteins that suppressmaturation of DCs andproliferation
and activation of cytotoxic cells. As a result, antigen presentation and cytotoxic activities plummet, practically eliminating immunosurveillance in the tumor milieu. Additionally, B cells
proliferate, but are not activated, turning them into tumor-promoting BREGs.M2macrophages recruit MDSCs to the TME, further reinforcing the positive feedback loop of Th2, M2, and N2
proliferation and activation, resulting in substantial increases in tumor-promoting inﬂammation and concomitant angiogenesis.
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B-cell function, particularly in tumor immunoediting is not well
understood [88].5.2. Th2 inﬂammatory cytokines
One of the primary effects of TGF-β in cancer immunoediting is in
promotion of a Th2 phenotype among T cell populations. TGF-β signal-
ing is mediated by homologs of Drosophila SMADs. In an investigation
by Kim et al., of the tumor suppressor gene for SMAD4, a central
mediator of TGF-β signaling, researchers found that T cells from
Smad4-deﬁcient mice were skewed toward a Th2 phenotype, with
high levels of IL-4, IL-5, IL-6, and IL-13 in supernatants of T cells [90].
Histopathology of the intestines of Smad4-deﬁcient mice revealed ab-
normal accumulation of immunoglobulin A-producing IgA+ plasma
cells inﬁltrates and massive increases in serum levels of IgA. This
correlated with the spontaneous progression of epithelial cancers in
the gastrointestinal tract of Smad4-deﬁcient mice.MDSCs also help to maintain Th2 cytokine expression. Returning to
effects of Gr-1+CD11b+ cells in the xenograft model of lungmetastases
by Yan et al., a broad-screen cytokine antibody array analysis of lung ly-
sates also demonstrated signiﬁcant elevation of MMP-9, basic-FGF/
FGF2, IGF-1, IL-1β, MCP-1/CCL2, SDF-1/CXCL12, and Th2 cytokines (IL-
4, IL-5, IL-9, and IL-10) in the premetastatic lung versus normal lung
[81]. They concluded that the shift of the Th1/Th2 balance was due pri-
marily to contributions by MDSCs. Thus, TGF-β has shown to have pro-
found effects on Th1/Th2 balance and myeloid cell lineages, including
Gr-1+CD11b+ immature myeloid cells, and chemokines, particularly
angiogenic cytokines appear to be very important in proliferation of
MDSCs.
5.3. Angiogenic chemokines
TGF-β also appears to be a critical driver of chemokine expression in
the TME; it has long been known that TGF-β signaling plays an impor-
tant role in angiogenesis [24,87,88,91]. Thus, it should also be no sur-
prise that many pro-angiogenic chemokines are prominent among the
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angiogenic chemokines include ELR + CXC chemokines, which contain
a signature Glu–Leu–Arg (ELR) sequence upstream of the CXC motif,
such as CXCL1-3/GROα-γ, ENA-78/CXCL5, and IL-8/CXCL8 [24]. Other
chemokines that are important in promoting angiogenesis include
SDF-1/CXCL12 [92] and MCP-1/CCL2 [93,94]. Secretion proﬁles of
MDSCs in a model of mammary carcinoma in mice deﬁcient in the
type II TGF-β receptor gene (Tgfbr2) provided signiﬁcant insight in
one example of TGF-β signaling supporting tumor-suppression instead
of tumor promotion and underscored the importance of immature my-
eloid Gr-1+CD11b+cells (MDSCs) and chemokines in tumor progres-
sion [95,96]. In Tgfbr2-deﬁcient mice crossbred with mouse strains
prone to spontaneous or inducible tumors, Yang, et al., found that in
Tgfbr2-deﬁcient mice MDSCs were speciﬁcally recruited to the TME,
leading to increased tumor cell survival and metastasis; 4 T1 tumor
size was proportional to local concentrations of MDSCs, mainly on the
invasive front of the tumor [95]. Antibody array analysis revealed in-
creased expression of TGF-β1, ENA-78/CXCL5, myeloperoxidase
(MPO), and MMPs in the TME; follow up experiments isolated produc-
tion of TGF-β to stromal cells, CXCL5 to tumor cells, andMPO andMMPs
to Gr-1 + CD11b+ myeloid cells. Flow cytometry demonstrated high
levels of CXCR4 expression in MDSCs regardless of Tgfbr2 status, sug-
gesting a mechanism by which Gr-1+CD11b+ cells can be recruited to
growing tumors by SDF-1/CXCL12 in the absence of TGF-β signaling.
Thus, MDSCs are such a critical component of tumor progression that
cancer cells must recruit them to the TME in the presence or absence
of TGF-β signaling via chemokine signaling.
In a companion study from the same lab, RT-PCR analysis demon-
strated increases in expression of mRNA for GROα/Cxcl1, ENA-78/
Cxcl5, and COX2/Ptgs2 in carcinoma cells from Tgfbr2-deﬁcient mice,
and antibody arrays conﬁrmed increased secretion of a number of
chemokines from tumors in Tgfbr2-deﬁcient mice, including GROα/
CXCL1, ENA-78/CXCL5, CXCL16, “regulated on activation, normal T-
cell-expressed and secreted” protein (RANTES/CCL5), MIP-1γ/CCL9,
and MIP-3α/CCL20 [96].
5.4. VEGF: a nexus for inﬂammation, angiogenesis
and immunosuppression?
The most prominent angiogenic cytokine, VEGF-A, is also immuno-
suppressive [96,97]. In fact, VEGF-A was actually the ﬁrst cytokine
ever identiﬁed that inhibits DC maturation [96,98], and VEGF signaling
is a lynch-pin connecting tumor-promoting inﬂammation and angio-
genesis in cancer [73]. Cytokine array-based detection of secreted pro-
teins from endothelial cells demonstrated that VEGF has an autocrine
effect on the release of proinﬂammatory cytokines via VEGFR2, inducing
increased secretion of IL-6, IL-8/CXCL8, and GRO-α/CXCL1 in endotheli-
al cells, but not in leukocytes [99]. Conversely, inﬂammatory cytokines,
primarily TNF-α, IL-1β, IL-6, and IL-8/CXCL8, can induce expression of
VEGF [73]. Additionally, hypoxia in the TME not only induces immuno-
suppression, as we have already discussed, but angiogenesis and
inﬂammation.
The synergistic, mutual reinforcement of expression between in-
ﬂammatory and angiogenic cytokines is virtually seamless, linking
VEGF and COX2 through hypoxia-induced and NF-κB signaling path-
ways [73,100]. Hypoxic conditions in the TME can induce expression
of hypoxia-induced factor 1-α (HIF-1α), which induces COX2; con-
versely, PGE2, a product of COX2, can induce expression of HIF-1α.
Moreover, the expression of IL-8/CXCL8 and other pro-angiogenic
and/or pro-inﬂammatory factors, including TNF, IL-1, IL-6, and IL-8/
CXCL8, are upregulated by hypoxic conditions via HIF signaling and hy-
drogen peroxide production and by NF-κB signaling [73,92]. For exam-
ple, Sakamoto, et al., used a cytokine antibody array to demonstrate
that 67% of colorectal cell lines they tested and 40% of colorectal cancer
tissues exhibited constitutive NF-κB activation and noted that promi-
nent effects of NF-κB signaling included increased expression of IL-8/CXCL8, MCP1/CCL2, and GRO-α/CXCL1, which was suppressed by
siRNA knockdowns of IκB kinase-γ [101]. VEGF also contributes to in-
ﬂammation and immunosuppression as a chemoattractant for macro-
phages, and tumor-educated macrophages are a signiﬁcant source of
VEGF, MMPs, and inﬂammatory factors, particularly M-CSF/CSF1,
which increases expression of VEGF; thus, a positive feedback loop can
be established between inﬂammation/angiogenesis and immunosup-
pression [59].
Extracellular matrix (ECM) proteases, particularly MMPs can pro-
mote both angiogenesis and inﬂammation by remodeling of ECM pro-
teins in the TME and surrounding tissues as well as releasing VEGF
and other angiogenic factors bound within the ECM. CAFs are an abun-
dant source of TGF-β, VEGF, COX2, and MMPs, and, thus are major con-
tributors to angiogenesis and inﬂammation in the TME [7,102]. Another
important contribution of CAFs is in expanding MDSC populations via
maintaining predominantly Th2 cytokine secretion patterns in the
TME, in which GM-CSF and IL-4 play prominent roles in tumor-
directed immunosuppression (see Fig. 8).
6. Unresolved issues in cancer immunoediting
6.1. Mast cells, GM-CSF and IL-4
The relationship of GM-CSF/CSF2 and IL-4 in immunoediting is quite
complicated. At low levels, GM-CSF and IL-4 or IL-13 lead to thematura-
tion of DCs, but at higher levels, GM-CSF appears to expand MDSC pop-
ulations [80]. GM-CSF is abundantly secreted by TAMs (Th2 cells), and
mast cells are known to secrete high levels of IL-4, IL-13, and GM-CSF.
Although little is known about the role of mast cells in cancer biology,
they have been characterized as “Jekyll and Hyde” contributors to can-
cer growth, and, notably, they have been shown to support polarization
ofM2macrophages (TAMs) and to secreteVEGF and IL-8/CXCL8, both of
which are potent activators of Th2/M2 inﬂammation and angiogenesis
[103].
However, a study published in Nature Immunology in 2000 suggests
that the level of GM-CSF and IL-4 expression may be irrelevant, and the
key to subvert these cytokines from the promotion of DCmaturation to
the expansion ofMDSCsmay be adding CAFs to themix. Chomarat et al.,
demonstrated that, in vitro, monocytes exposed to GM-CSF and IL-4 re-
sulted in their differentiation into antigen-presenting DCs; however
when ﬁbroblasts were added to the culture, the ﬁbroblasts began
pumping out IL-6 as soon as they contacted the macrophages. This
caused the macrophages to up-regulate expression of M-CSF/CSF1 re-
ceptors, setting up an autocrineM-CSF loop [104]. In the TME, M2 mac-
rophages are attracted by M-CSF and are a primary source of secreted
M-CSF. In amore recent study, targeting CAFswith vaccination for ﬁbro-
blast activation protein (FAP) in an animal model resulted in the rever-
sal of the predominance of Th2 over Th1 cells and immunosuppressive
cells over CTLs and APCs in tumor milieu [102]. This anti-FAP treatment
also resulted in lower expression of GM-CSF in the TME, as well as re-
duced expression of VEGF and another pro-angiogenic factor,
placental-derived growth factor C (PDGF-C).
6.2. Neutrophils: N1/N2 balance and TANs
While much research has been done on the roles of TAMs in cancer,
until recently, little attention has been given to TANs (tumor-associated
neutrophils), which also have tumor-suppressing (N1) and tumor-
promoting (N2) phenotypes [105,106]. The roles of these innate im-
mune cells in cancer are not well characterized, possibly due to their
being considered “short-lived” compared to other immune cells.
However, the prominence of angiogenic chemokines in the TME,
which promotes the chemoattraction of N2 neutrophils, argues for
their importance [107]. In the innate immune response, neutrophils
(also known as polymorphonuclear leukocytes or PMNs) are primarily
involved in ﬁghting off microbial infections and wound healing.
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centrations of serine proteinases (including matrix metalloproteinases,
or MMPs), antimicrobial peptides (e.g., defensins), and ROS [108]. Be-
cause of their cytotoxic contents, release of the contents of neutrophil
granules is normally under tight control. N2 neutrophils also secrete
high levels of cytokines that induce angiogenesis and inﬂammation, in-
cludingVEGF,MMP-9,MCP-1/CCL2, and IL-8/CXCL8. Amonghuman im-
mune cells, CXCR2, a receptor for many angiogenic chemokines, is
expressed almost exclusively in neutrophils and mast cells [109]. Addi-
tionally, Jamieson et al., demonstrated that blocking CXCR2 activity in a
mouse xenograftmodel, either by Cxcr2 deﬁciency or by CXCR1/2 inhib-
itors, reduced neutrophil inﬁltration, lowered tumor-associated inﬂam-
mation and substantially decreased benign and malignant tumor
burdens [109].
Thus, TANs are actively recruited to the TME and they likely play an
important role in inﬂammation and angiogenesis, but N2 neutrophils
also secrete large amounts of cytokines that suppress immune response,
including TGF-β, IL-10, MCP-1/CCL2, MIP-1β/CCL4 and macrophage
migration inhibitory factor (MIF) [105,107]. TANs also promote B cell
proliferation, maturation, and survival by the expression of “a
proliferation-inducing ligand” (APRIL or TNFSF13) and B-cell activating
factor/B lymphocyte stimulator (BAFF/BLys or TNFSF13B) [107]. Secre-
tion of these cytokines suggests that TANs may play an important role
in cancer immunoediting in general and, speciﬁcally, in maintaining
and training of B cell populations in the TME. Understanding the role
of N2 neutrophils in the “education” of tumor-associated B lymphocytes
may provide a large piece of this puzzle, as the role of B cells in tumor
progression and escape is not well understood either.
6.3. Regulatory B lymphocytes: enter the BREG
B cells are responsible for the release of antibodies associated with
the humoral immune response; activated B cells are crucial in antigen
presentation, and B-lymphocyte depletion has been shown to be effec-
tive in ameliorating symptoms of auto-immune diseases [110]. Thus,
why increased B cell activity would be tumor-promoting rather than
tumor-suppressing is not immediately apparent, and although the po-
tential tumor-promoting functions for B lymphocytes was postulated
over 50 years ago, their role in cancer progression is still largely
unknown [21]. Nonetheless, the inhibition of antigen presentation asso-
ciated with regulatory B cells (BREGs) may represent a crucial contribu-
tion to cancer immunoediting, as underscored by the paradoxical
observation that the presence of cancer-related autoantibodies in
serum or TMEs is often correlated with poor patient survival [6]. The
immunomodulators APRIL and BAFF/BLys, presumably secreted by N2
neutrophils, have been detected in breast carcinomas and other tumors
[21,107]. It has been suggested that, in the TME, these cytokines
may help to maintain tumor-promoting B cells, which secrete IL-6 and
IL-10 [6,21]. Collectively, these cytokines help support M2 polarization
in TAMs, inhibit cytotoxic activity and antigen presentation in macro-
phages, and prevent thematuration of themajor contributor to antigen
presentation, DCs.
6.4. IL-17, IL-23 and Th17 cells
Th17 cells are a fourth type of T helper cell phenotype that is distinct
from Th1, Th2, and Treg cells, but all come from the same immature T
helper progenitor, Th0 (see Fig. 6). Th17 cell differentiation is typically
induced by TGF-β, IL-6, IL-1α, IL-1β and IL-23, and Th17 cells are
characterized by the production of IL-17, IL-2, GM-CSF/CS2, IFN-γ, and
TNF-α [111]. Since Th17 cells are best known for their involvement in
the pathogenesis of various autoimmune diseases, one might assume
that Th17 cells might then play a role in supporting antitumor immuni-
ty. However, the role in tumor biology of IL-17 and of the T helper cell
type associated with IL-17 and IL-23, Th17 cells, are poorly understood
and may be tumor-suppressing [25,112] or tumor-promoting [25],depending upon the context, and the mechanisms of these effects are
unclear [25,113].
For example, when Kesselring et al., investigated the role of Th17
cells in patients with head and neck squamous cell carcinoma
(HNSCC) [25,114], they found that circulating Th17 cells were elevated
in HNSCC patients and represented a large fraction of tumor-inﬁltrating
lymphocytes. A bead-based multiplex ELISA revealed that Th17 cells in
the HNSCC tumor milieu secreted IL-1β, IL-6, and IL-23; this was con-
ﬁrmed by ELISA and ﬂow cytometry. Kesselring et al., also noted that
proliferation of HNSCC cells in vitrowas inhibited and that the apoptosis
and necrosis of HNSCC cells increased proportionally with the number
of Th17 cells seeded in co-culture. However, antibody array analysis re-
vealed that, compared with monocultures of HNSCC, co-culturing with
Th17 cells resulted in a net increase in many pro-angiogenic cytokines
and a net decrease in several anti-angiogenic proteins. Most recently,
the relationship between Th17 cells and angiogenesis has been
strengthened by a report in Nature in which IL-17 and Th17 cells have
been implicated in tumor resistance to anti-angiogenic therapy by in-
ducing CAFs to increase expression of granulocyte-speciﬁc CSF (G-CSF
or CSF3), a known factor in the recruitment and expansion of MDSCs
[115].
In unraveling the mystery behind the dual role of Th17 cells in can-
cer progression and antitumor response, it may be helpful to look at the
relationship of IL-12 to IL-23, a cytokine closely associated with the
Th17 helper phenotype. With regard to cancer immunoediting, other
than TGF-β and IL-6, the only cytokine associated with Th17 cells with
a role that is fairly well established is that of endogenous IL-23. A
heterodimer of IL-23/p19 and IL-12/p40, IL-23 appears to suppress
tumor immune response, while a related cytokine, IL-12, a heterodimer
of IL-12/p40 and IL-12/p35, enhances antitumor immunity; these
activities are inversely regulated in the TME via activation of STAT3
signaling, resulting in IL-23/p19 production in TAMs being upregulated
and in IL-12/p35 gene expression being downregulated in tumor
associated-DCs [116].
6.5. Interleukin-2 and interleukin-15
Early in the age of molecular biology, interleukin-2 (IL-2) was
considered as a possible cancer therapy to boost immune response to
tumor-associated antigens [117]. This made sense, as IL-2 was known
as a potent stimulator of the immune response, particularly in the de-
velopment and expansion of effector T cells. Trials of cancer patients
with high doses of IL-2 have been reported in the literature since the
mid 1980s [118,119]. Several large clinical studies have examined the
effectiveness and adverse events of IL-2 therapy in hundreds patients
[120–122]. Considered together, these clinical trials showed a relatively
low risk of severe side effects associated with IL-2 therapy in various
combinations, but the overall effectiveness was also very low, with
only 10–20% of patients showing partial or complete remission of can-
cers. However, most patients who did respond to IL-2 therapy remained
cancer-free for extended periods.
Fever is a common side effect of IL-2 treatment, and this effect has
been primarily attributed to induction of TNF-α [123]. This suggests
that at least part of the mechanism by which IL-2 exerts clinical antitu-
mor activity is through induction of TNF-α, but, for all practical intents,
we know little of the mechanism of IL-2's antitumor activity or of the
mechanisms by which normal IL-2 activity is suppressed by tumors.
Part of the reason that IL-2 may have poor effectiveness as an immuno-
therapy of cancer could be that IL-2 appears to increase in vitro expres-
sion of FOXP3 (a regulator of immunosuppression) in TREGs and has
been shown to induce the expansion of TREGs in peripheral blood
in vivo [124]. Additionally, TGF-β and IL-2 are known to induce differen-
tiation of naive Th0 cells to TREGs, as the combined treatment of
CD4+CD25− cells with TGF-β and IL-2 is necessary and sufﬁcient to
induce expression of CD25 and FOXP3 in naive Th0 cells [125]. This sug-
gests that combination therapy of recombinant IL-2 with inhibitors of
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more research needs to be done on the role of IL-2 in cancer
immunoediting, and multiplexed immunoassays, such as antibody
arrays, could be very helpful in elucidating those mechanisms.
Also, IL-15 is structurally very similar to IL-2, shares some of its re-
ceptor components, and can mimic IL-2-dependent T cell proliferation
[126,127]. However, its biology is somewhat different and suggests a
more pleiotropic role in cancer biology. For example, IL-15 signaling in
mast cells and ﬁbroblasts can protect these cells from apoptosis, and
in neutrophils, it can also inhibit neutrophil apoptosis and stimulate
their expression of IL-8/CXCL8. IL-15 also appears to have potential
roles in both innate and adaptive immunity. However, IL-15 therapy
has recently emerged as a potentially immunotherapy for cancer;
recombinant IL-15 therapy appears to induce differentiation of T, B
and NK cells, activate CTL cells, and promote the maturation of DCs
[127,128].
7. Implications for cancer immunotherapy
7.1. The importance of antitumor immunity in long-term, progression-free
survival
Long-term survival of the patient is considered the “gold standard”
of success in cancer treatment, but, from the patients' perspective,
disease-free survival is the ultimate goal. In practice, using disease-
free survival as an endpoint in a clinical trial is challenging, particularly
for advanced and metastatic cancers [73,129,130]. The primary
methods of cancer treatment are resection (surgical), small-molecule
chemotherapy, radiotherapy and biological therapies (which could in-
clude cytokines, antibodies, proteins, genes and vaccines). Many of the
approaches to biological therapy employ techniques of immunotherapy.
As mentioned in Section 2.1, immunotherapy of cancer is not a new ap-
proach. The administration of cytokines, such as TNF-α, IFN-γ, or IL-2,
and even the transfer of tumor inﬁltrating lymphocytes (TLK) or
lymphokine-activated killer (LAK) cells to boost antitumor activity has
been used since the 1980's [131]. Recently, great strides have been
made in immunotherapies, which appear to be ﬁnally coming of age
and are showing great promise for advancements in cancer survival.
However, the relative efﬁcacy of immunotherapy has been greater as
an adjuvant in treating patients with operable disease at high risk for
postoperative recurrence rather than patients with advanced disease
[117].
The question that begs to be answered is whether long-term survival
and disease-free survival are largely dependent upon enhancing the
patient's own immune system tomount an effective antitumor response
and, if so, how to deﬁne such a response. As we noted previously, among
tumor-bearing mice beneﬁting from C. noyvi-NT infection (Section 2.1)
and cancer patients who responded to IL-2 therapy (Section 6.5), antitu-
mor immunity that is sufﬁcient to eradicate tumors endures long after
the tumors are gone. Several studies have also noted that the appearance
of autoimmune symptoms, prior to diagnosis or as a result of immuno-
therapy, is a positive indicator of patient survival and prognosis.
Among thyroid cancer patients, prior history of thyroid autoimmune dis-
ease or the presence of serum thyroid autoantibodies was a statistically
signiﬁcant indicator of positive outcome [132]. One group reported in
2006 that, amongmelanoma patients treated with IFN-α2b, the appear-
ance of autoimmune symptoms was an independent indicator of both
overall survival and relapse-free survival [133], but later admitted that
retrospective studies were less conclusive [134]. Most recently, studies
with ipilimumab (anti-CTLA-4 treatment) revealed that favorable out-
come in patients with stage IV melanoma was associated with
“immune-related adverse events” and that these side effects were man-
ageable in most patients [135]. Thus, evidence of a strong immune
response to therapy, even to the point of inducing autoimmune symp-
toms, may be a positive indicator of long-term survival in cancer patients.
Another strong indicator that immune response may be essential fordisease-free survival is a study of the immune cell inﬁltrates of tumor bi-
opsies from a large cohort of cancer patients that was published in Onco-
gene in 2010; in this study, tumor inﬁltration by larger proportions of
memory T cells, particularly Th1 and CTLs, was the strongest prognostic
factor for disease-free progression [29].
Another consideration is the extent towhich the success of standard
(non-immunotherapy) treatments of cancer may be the result of im-
mune response instead of removing or directly killing cancer cells. For
example, in one study, radiation or neoadjuvant hormone treatment
of prostate cancer resulted in the release of signiﬁcant levels of autoan-
tibodies detecting TAAs in some patients [136]. An investigation from
NatureMedicine in 2007 reported thatmuch of the effectiveness of con-
ventional treatments, such as chemotherapy and radiotherapy, may be
due to innate and adaptive antitumor responses in humans and mice
via toll-like receptor 4 signaling in dendritic cells, presumably in re-
sponse to the release of TAAs [137]. These are but two examples in a
growing body of evidence that suggest to some cancer researchers and
oncologists that, to some extent, the effectiveness of many—if not all—
conventional treatments of cancer may be due to their ability to induce
an antitumor immune response [138,139].
These same authors argue that, as a logical extension of the supposi-
tion that standard cancer treatments may elicit an immune response in
some patients, a third consideration is the extent to which immune-
boosting therapies can augment standard anti-cancer therapies. Other
groups are working on the development of an “immunoscore” to corre-
late objective measures of antitumor immune response to patient prog-
nosis [29,140,141]. Our model strongly suggests that most, if not all,
successful cancer treatments should increase objective measures of an-
titumor immunity, regardless of themode of treatment. One study sug-
gests that detection of autoantibodies for TAAs may be an important
marker of antitumor immunity [136], which might easily be accom-
plished using a protein microarray spotted with TAAs to probe patient
serum or plasma for autoantibodies recognizing these antigens.
7.2. Targeting TREGs and T cell anergy: anti-CTLA4 and anti-PD-1
The importance of TREGs in tumor-directed immunosuppression also
suggests that an increase in cytotoxic cell inﬁltration of tumors—and
therefore cytotoxic antitumor activity—could be accomplished by
disruption of the expansion and maintenance of TREG populations and/
or the inhibitedmaturation of DCs that contributes to larger populations
ofMDSCs. TREGs andMDSCs suppress Th1 polarizationwithout affecting
overall T cell proliferation and inhibit cytotoxic effects in CTLs and NK
cells, primarily through the expression of IL-10, TGF-β, IL-27, IL-35,
soluble Fas ligand (FasL) and galectin-1 (LGALS1) [21,25]. TREGs block
Th1 differentiation by inhibiting the production of IFN-γ and IL-2, as
well as inhibiting Th1 cell activation by antigen-presenting cells
(APCs). The binding afﬁnities of B7-1 and B7-2 with CTLA-4 are some-
what stronger than with CD28, so CTLA-4 expression by TREGs can
effectively shut down effector T cell functions if they are in large num-
bers in the TME (see Fig. 4)—particularly in cooperation with MDSCs
(see Fig. 7 and Section 7.3). Depletion or neutralization of TREGswith an-
tibodies to receptors commonly expressed on their surface, such as
CD25, glucocorticoid-induced TNFR-related protein (GITR or TNFRSF18)
and/or cytotoxic T-lymphocyte antigen 4 (CTLA-4), improves immune-
based clearance of tumors and enhances the response to immune-based
therapies. Similar results have been seen using cyclophosphoamide
therapy, which appears to deplete TREGs, albeit not selectively [80].
CTLA-4 and PD-1 have emerged as prime targets for immunotherapy
using antibodies to target immunosuppression by TREGs and PD-L1 ex-
pression on tumor cells [47,142]. Ipilimumab (anti-CTLA-4) is the only
such antibody that is currently FDA-approved. Clinical trials using a nu-
merous combination therapies with ipilimumab are currently ongoing
or plannedwith a wide range of other therapies, including recombinant
cytokine immunomodulators, small molecule immunomodulators,
antibodies targeting other proteins, various chemotherapies, and
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ty of the various ipilimumab combination treatments in melanoma pa-
tients. Tremelimumab (also anti-CTLA-4) and nivolumab (anti-PD-1),
as well as a number of other antibodies targeting PD-1 and its ligand,
PD-L1, are under investigation. As noted in Section 7.1, a number of
novel immune related adverse events have been noted with the use of
ipilimumab that were not revealed in pre-clinical studies or animal
models, and combinations of anti-CTLA-4 and anti-PD-1 antibodies ap-
pear to generate overlapping and unique toxicities [142].
7.3. Targeting TREG interactions with MDSCs and Th17 cells
One crucial aspect of targeting TREGs that should not be overlooked is
the ability ofMDSCs to expandTREG populations in the presence of IFN-γ.
CD40 expression onMDSCs interacting with CD40L on TREGs in the pres-
ence of TGF-β and IL-10 appears to be necessary for the expansion of
TREGs, as MDSCs from Cd40-deﬁcient mice and mice treated injected
with anti-CD40 were unable to expand TREG populations and exhibited
higher levels of tumor-speciﬁc T-cell immune response [84]. As noted
in Section 7.2, TREGs also block production of IFN-γ and IL-2 and suppress
effector Th1 cell activation by antigen-presenting dendritic cells [83].
Further, IFN-γ appears to increase the expression of CD40 [84], IL-10,
and TGF-β by MDSCs [85]. Thus, the interactions of MDSCs and TREGs
via CD40/CD40L and IFN-γmay help to explainwhy tumor immunosup-
pression is resilient—even under treatmentwith IFN-γ (see Fig. 7). Based
upon the model that we have proposed for the relationships between
tumor cells and immune cell populations, it is clear that the proliferation
of MDSCs and TREGs and the subsequent inhibition of Th1, M1, and
APC populations in the TME is a likely explanation of the failure of
IFN-γ- and IL-2-based therapies, as the effects of IL-2 are largely
based on induction of IFN-γ expression. Thus, targeting MDSCs may
be essential to reducing the tumor-supportive immune suppression
by TREG cells.
Finally, there may be reason to consider leveraging the apparent
inverse relationship between Th17 cells and TREG cells in the TME. Part
of the reason that the role of Th17 cells in cancer biology is so fuzzy
may be that, in contrast to Th1 and Th2 cells, Th17 and TREG cells appear
to be more plastic and potentially inter-convertible [143]. In cancers,
Th17 levels in the TME tend to correlate directly with the number of
Th1 cells, CTLs, and NK cells and inversely with TREGs [144]. There is
also an inverse relationship between the differentiation of Th17 and
TREG cells in autoimmune disorders [113]. It has been shown that co-
treatment with IL-6 and TGF-β may induce the conversion of mature
TREG cells into Th17 cells [145]. Moreover, exposing Th17 cells to IL-12
may re-polarize them to a Th1 phenotype, and treating Th17 cells
with IL-4 results in re-polarization to a Th2 phenotype [146]. Crucially,
conversion of mature Th17 cells to TREGs has not been reported [143].
Thus, it may be possible that immunotherapy targeting TREGs in an
attempt to convert them to Th17 cells or attempting to convert existing
or induced pools of Th17 cells in Th1 populations within the TME,
directly or indirectly, may be viable strategies, with the net result
being increases in both cytotoxic antitumor activity and APC activity.
7.4. Anti-angiogenic/anti-inﬂammatory co-therapies
In the ideal situation, inﬂammation should help to enhance antitu-
mor immunity and promote tumor clearance. This much was clear
from the results of Agrawal et al., in examining Coley's observation, as
noted in Section 2.1 [20]. Based upon themodel outlined in this review,
it is clear that a primary goal of immunotherapy should be to shift the
Th1/Th2 balance toward a Th1 phenotype andmacrophage populations
toward a predominantlyM1 phenotype to enable increased maturation
of DCs, which is critical for adaptive antitumor immune responses. In-
deed, this has been demonstrated in vivo. However, our model demon-
strates that, in the TME, the predominant phenotype of CD4+ cells is
Th2, while M2 is the predominant macrophage phenotype in the TME,as N2 is for neutrophils. In addition, TGF-β appears to play a pivotal
role in tipping M1/M2 (see Section 4.2) and N1/N2 balances in favor
of tumor-promoting inﬂammation by macrophages and neutrophils,
respectively [106].
We have also outlined the close intertwining of VEGF and COX2 in
promoting angiogenesis andM2-type inﬂammation to themaintenance
of immune cell populations in the TME that suppress anti-tumor immu-
nity, primarily by inducing the inhibiting the differentiation and activi-
ties of APCs andby proliferation ofMDSCs (see Figs. 5 and 8). As noted in
Section 7.3, MDSCs help to proliferate TREGs in the presence of IFNγ, and
TREGs tend to inhibit expression of IFN-γ and IL-2, and TREGs inhibit Th1
and M1 polarization by blunting the expression of IL-12 and increasing
expression of IL-10. In addition, TNF-α (a Th1 cytokine) is also a strong
inducer of the NF-κB pathway, which is central to the maintenance of
tumor-supporting inﬂammation and angiogenesis, so in the absence of
IL-1 and IL-12, TNF-α and IL-6 may be more likely to induce inﬂamma-
tion and angiogenesis than to tip the balances to tumor-suppressive
inﬂammation.
Moreover, considering the crucial role of Th2 and M2 cytokines in
inhibiting DC maturation, and the fact that immature DCs are a signif-
icant source of TGF-β, as well as the importance of the APC activity of
DCs in mounting an effective antitumor immune response, without
further investigation it may be presumptuous to assume that the im-
portance of COX2 and PGE2 in tumor progression or as targets in can-
cer therapy resides in more their tumor-promoting activities of
inﬂammation and angiogenesis than in immunosuppression. Thus,
we propose that the introduction of anti-angiogenic and/or anti-
inﬂammatory therapies should be investigated as co-therapies that
may boost the effectiveness of cancer immunotherapies, or, indeed,
any mode of cancer therapy. A summary of several therapies sug-
gested by the current model of tumor-induced immune suppression
and the predicted results are summarized in Fig. 9. For example,
immunotherapies may be enhanced by additionally targeting one
or more pro-angiogenic/pro-inﬂammatory markers, such as COX2,
VEGF, or IL-8, or perhaps with inhibitors of IL-6 (a suppressor of DC
maturation), or even IL-10.
Based upon themodel we have proposed for the nexus of angiogen-
esis, Th2 inﬂammation and immunosuppression (Figs. 5 and 9), IL-12
also stands out as a strong potential candidate to break the stranglehold
of Th2/M2 and MSDC populations that promote not only immunosup-
pression to allow escape from immunoediting, but also inﬂammation
and angiogenesis that further support tumor progression. As an exam-
ple of these types of investigations, a recent publication by Zhang
et al., suggests that timing of these combinations of immunotherapy
and conventional therapies may be critical [147]. Although IL-12 has
been approved for cancer therapy for some time and showed great
promise in mouse models, clinical results of IL-12 used as stand-alone
therapies resulted in severe toxicities in some cancer patients [148].
However, Zhang et al., may have discovered that timing is a key element
to the successful use of IL-12 that may also help to limit its toxicity by
narrowing the treatment window. In their in vivo mouse model, IL-12
was administered to each mouse only three times (every other day),
as monotherapy or as co-therapy commencing at three, six or nine
days after chemotherapy. Treatment with IL-12 alone was ineffective
in shrinking either immunogenic or poorly immunogenic tumors, and
co-therapy with IL-12 commencing at six or nine days after
cyclophosphoamide, gemcitabine or doxorubicin chemotherapy was
actually worse than IL-12 alone. However, when IL-12 treatment com-
menced three days post-chemotherapy, both immunogenic and poorly
immunogenic tumors shrank dramatically. According to ourmodel, two
possible explanations of this are 1) the ability of IL-12 to enhance anti-
gen presentation by promoting the maturation of immature DCs and 2)
binding of IL-12 to IL-12 receptors on activated T cells. Notably, other
strategies used to deplete MSDC and TREG populations in this same
study were not nearly as effective as IL-12 administered three days
after chemotherapy.
Fig. 9. Implications of tumor-induced immunosuppression for cancer therapy. Since tumor-promoting Th2,M2, N2 andMDSC activities are allmutually self-reinforcing and generally pro-
mote inﬂammation and angiogenesis as well as immunosuppression, therapies that target inﬂammatory and angiogenic factors (such as anti-VEGF immunoglobulin or NSAIDs) may be
synergisticwith immunostimulatory treatments, suchas recombinant IL-2, IFN-γ, TNF-α,IL-12 or IL-18 (or combinations thereof). Additionally, the central roles of TGF-β, IL-10, IL-6 and IL-
4 in the positive feedback loop supporting Th2, M2, N2 and MDSC populations (and inhibiting their tumor-suppressing alternative phenotypes) and inhibition of DC maturation make
these potential targets for antitumor therapies. Overall, this model suggests that any successful cancer therapywill likely improve antitumor immune response and that immunotherapies
may beneﬁt from complementary strategies for targeting Th2, M2, N2 and MDSC populations and/or their tumor promoting effects on inﬂammation and angiogenesis.
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dominance of Th2 cells andM2macrophages in the TME, reinforced and
protected byMSDCs, in favor of tumor-suppressing Th1/M1 andmature
DC populations represents a necessary prerequisite to any effective an-
titumor immune response. As Th1 and M1 populations normalize and
APC functions are restored, antitumor immune responses should soon
follow.
7.5. Interleukin-18 (IL-18)
Since the late 1990s, it has been known that IL-18 can suppress
tumor growth in mice by increasing NK and activated CD4+ T cells in
a mechanism that was independent of IFN-γ and IL-12 [149]. IL-18, as
its alternate name “IFN-γ-inducing factor” suggests, was ﬁrst identiﬁed
as an inducer of IFN-γ [150]. Indeed, as depicted in Fig. 6, IL-12 and IL-18
are the two factors that promote the maturation of Th1 cells from im-
mature Th0 progenitor cells, and Th1 cells are signiﬁcant source ofIFN-γ. Also, mature DCs are thought to be a signiﬁcant source of IL-12
and IL-18, and the current model of tumor-induced immune escape is
characterized by a lack of mature DCs and the concomitant expansion
of immunosuppressive MDSCs. This suggests (as depicted in Fig. 9)
that, in addition to IL-12, treatment of cancer patients with IL-18 may
tend to tip the Th1/Th2 balance toward the Th1 (tumor-suppressing)
phenotype. However, IL-18 levels tend to be elevated in many cancer
patients, and these elevations have been associated with disease pro-
gression, poor clinical outcome and survival [151]. In particular, there
is evidence that a positive feedback loop between IL-18 and VEGF
expression in some cancer cells and that IL-18 can stimulate metastasis
and migration [152]. Among other tumor-promoting effects, IL-18
appears to allow certain cancers to escape immune recognition
[151,152]. Recently, it was shown that IL-18 can induce expression of
programmed cell death 1 (PD-1) in NKs and that the prometastatic ef-
fects of IL-18 in nude mice were dependent upon PD-1 receptors
[153,154]. Another aspect of the investigation of the role of IL-18 in
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that appears to be induced by IFN-γ as part of a feedback regulation of
IL-18 [155]. In the presence of NK cells, administration of IL-18 bp
resulted in metastatic lung tumor regression [155].
Nonetheless, IL-18 may provide an opportunity for cancer immuno-
therapies. In particular, the safety proﬁle of rhIL-18 is quite attractive
[156,160]. Conventional therapies using recombinant IL-18 in combina-
tion with other drugs have shown great promise [156,157] and are cur-
rently being tested for effectiveness in patients in clinical trials. “Helper”
NK cells primed with IL-18 alone or in combination with other
immunostimulatory cytokines appear to have great promise, demon-
strating signiﬁcant antitumor activities [156,158,159]. Also, several
studies have indicated that co-treatment with IL-18 and IL-2 may en-
hance cytotoxicity and expansion of NK cells in vivo [156,161].
7.6. TGF-β Inhibitors as part of cancer immunotherapy
TGF-β signaling is arguably the single most important cytokine sig-
nal pathway in cancer progression. First, because TGF-β is considered
to be tumor-suppressive in primary tumorigenesis but tumor-
promoting in later stages [87,162]. Second, TGF-β signaling induces or
reinforces the expression of nearly all of the other cytokines and other
secreted proteins that help to support not only immunosupression,
but also , as we have seen, inﬂammation and angiogenesis. Moreover,
TGF-β andTGF-β-induced factorsmay also serve as valuable biomarkers
for assessing the degree or extent of tissue invasion and metastasis in
various cancers. For, example, in a recent investigation by Robert
Weinberg's group, (Scheel et al.), screening cultured media with a
high-density antibody array detecting 507 proteins revealed several fac-
tors related to TGF-β and Wnt signaling that were differentially
expressed during epithelial-to-mesenchymal transitions, and follow
up experiments conﬁrmed that these were important contributors to
both TGF-β and Wnt signaling [87,163], as well as invasion and
metastasis [87,163].
The effectiveness of therapies targeting TGF-β is under investigation.
Many potential drug candidates targeting TGF-β are currently under de-
velopment or investigation, including antisense RNAs, sequestering li-
gands of TGF-β and small molecule inhibitors of TGF-β signaling. For
example, tumor vaccine efﬁciency has been shown to increase in con-
junction with inhibition of TGF-β, and no single source of TGF-β has
been identiﬁed as being critical for this function; therefore global inhibi-
tion of TGF-β from many sources may account for the effectiveness of
this treatment [87,113]. However, due to the dual nature of TGF-β in
cancer tumorigenesis and progression and the pervasive heterogeneity
of tumors, much work will be needed to screen for and validate the ge-
netic and proteomic markers that would identify both cancer types and
individual patients most likely to beneﬁt from TGF-β inhibitors in com-
bination with other cancer therapies [91].
8. Conclusion
As revealed by high-throughput screening technologies including
those based upon antibody arrays, the process of tumor-induced
suppression of cancer immunosurveillance is dependent upon re-
cruitment of CAFs, TAMs, TANs, MDSCs, TREGs and other cells that
alter the balance of immune cell populations in the TME. The net re-
sult is increased inﬂammation and angiogenesis, as well as increased
transition of neutrophil phenotypes from N1 to N2, macrophages
from M1 to M2, and T cells from Th1 to Th2, as well as a decrease
in the number and activity of CTLs and APCs. Substantially lower
populations of mature DCs provide a larger pool of monocyte precur-
sors to support growing M2 and MDSCs populations. Subsequently,
the cytokine networks established between and among these im-
mune cell types are mutually reinforcing and serve to collectively
maintain immune cell populations in the tumor milieu that are
predominantly tumor-promoting instead of tumor-suppressing.Moreover, it appears that TGF-β, VEGF, HIF-1α, COX2 (and its prod-
uct, PGE2), angiogenic chemokines, and inﬂammatory cytokines
(particularly Th2-induced cytokines) are all at located the nexus of
tumor-induced angiogenesis, inﬂammation and immunosuppres-
sion. This nexus appears to be maintained by the mutual reinforce-
ment of Th2, M2, N2, TREG and MDSC populations via IL-4, IL-6, IL-
10, and TGF-β with support by CAFs and BREGs (see Figs. 5, 8, and
9). Absent disruption of mutual reinforcement of the predominant
Th2, M2, N2, MDSC and TREG populations in the TME, prospects for
mounting an effective antitumor immune response seem dim.
Moreover, our model and a growing body of evidence suggest that
the establishment of an effective antitumor immune response in each
cancer patient may be essential to the success of any antitumor thera-
pies, regardless of modality. Thus, no matter what modalities or combi-
nations of antitumor therapies are used in the clinical treatment of
cancer, it is apparent thatmonitoring changes in the patient's antitumor
immune response is critical feedback to determine the success of those
treatments and the ultimate prognosis of the patient. Based upon our
model, and the pioneeringwork of others in tumor immunology, we be-
lieve that some kind of “immunoscoring” that evaluates changes in im-
mune response should become part of the routine evaluation of
treatment efﬁcacy in every cancer patient.
Much work may still need to be done in vitro, in animal models
and in characterizing samples from cancer patients to better ﬁll out
the theoretical framework to establish whether this scoring should
evaluate the recruitment, differentiation, proliferation, activation/
polarization of immune cells in the TME and/or in peripheral blood.
As with everything else in cancer biology, strategies may well depend
not only on the type of cancer, but also on the actual gene and protein
expression proﬁles as well. Gene expression experiments may be very
useful in pinpointing signal transduction pathways that are being acti-
vated in patient tumor biopsies or in vitro tumor cultures. Shifts in re-
cruitment, differentiation and proliferation of immune cell populations
can easily be determined by cellular markers, using IHC or ﬂow cy-
tometry, but assessing changes in the activation and polarization
statuses would be best accomplished by monitoring cytokine expres-
sion panels by multiplexed immunoassays. Elucidating the roles of ad-
ditional cytokines and transcriptional factors that affect cytokine
proﬁling may shed additional light on the complex network of secret-
ed cell–cell signals that shape normal antitumor immunity and patho-
logical, tumor-induced immunosuppression. Cancer antigen arrays
should be used to screen for the emergence of higher titers and
changes in the diversity of patient autoantibodies to TAAs in response
to treatment, regardless of modality. Autoantibodies to speciﬁc TAAs
themselves may represent biomarkers of prognosis or survival. Finally,
all of these investigations should include components to establish cor-
relations between patient prognosis and survival with changes in spe-
ciﬁc cytokine levels and activation signal transduction pathways, as
well as changes in reactivity in patients' autoantibody populations to
TAAs and changes in immune cell populations in the both TME and
peripheral blood.
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